As the trend of shifting the site of infusion services from the physician office to the hospital outpatient department continues, so does the conversation about the revenue differences in doing so.
Now that ICD-10 has become a reality, oncology practices are still going to face uncertain income, unready payers, delays in payment, and possible take-backs of paid monies following audits after the fact.
A smart investor needs to fully comprehend how risk is measured and its potential effect on long-term portfolio performance. This article outlines 5 principles of investment management that can increase your chance of success.
The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of breast cancer. Although new claims cannot be submitted with ICD-9-CM codes as of 10/1/15, these may still be needed for submitting old claims that occurred before 10/1/15. We will, therefore, continue to provide the 2 sets of codes through the end of the year.
Would the first impression a patient has of your practice send a safety message? You see, first impressions do count! The way your office appears will hopefully send the message of a well-organized, efficient, safety-centered practice.
Personalized medicine gained a national platform with the January 2015 proposal by President Barack Obama to analyze genetic information from more than 1 million American volunteers, as part of a new initiative to understand human disease and develop medicines targeted to an individual’s genetic makeup. The president included a $215-million line item in his proposed 2016 budget to fund this initiative.
The following trials represent a selection of key clinical trials that are currently recruiting patients with breast cancer for inclusion in investigations of new therapies for breast cancer. Each trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their appropriate patients to one of these clinical trials.
States have long been recognized as incubators for new policy models, and health policy is no exception. We have seen a multitude of approaches to health insurance and delivery taken up by states after the passage of the Affordable Care Act (ACA). States have chosen to create their own exchanges, defaulted to the federal exchange, or opted for a middle ground with state partnership and federally supported exchanges.
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015. Overall, 61% of women with breast cancer are diagnosed while the disease is confined to the breast; for these women, the 5-year survival rate is 98.6%. However, for women with metastatic breast cancer, the 5-year survival rate falls sharply, to 26%.
Results 1 - 9 of 9